New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
06:52 EDTINSYInsys Therapeutics reports Q1 EPS 23c, consensus 28c
Reports Q1 revenue $41.6M, consensus $45.63M.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:24 EDTINSYJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
May 20, 2015
13:10 EDTINSYInsys Therapeutics weakness a buying opportunity, says RBC Capital
Subscribe for More Information
12:25 EDTINSYInsys Therapeutics drops following arrest of Alabama doctors
Shares of Insys Therapeutics (INSY) are sharply lower in early afternoon trading after FOX10 News in Alabama reported that Dr. John Patrick Couch and Dr. Xiulu Ruan of Physicians' Pain Specialists of Alabama Pain Center have been arrested on drug and fraud charges. Previously, the Southern Investigative Reporting Foundation stated that Ruan and Couch were the leading prescription writers of Subsys, which is Insys' sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients, by an "impressive margin." Shares of Insys are down 8.4% to $54.76 in afternoon trading following the news of the arrests of the doctors. Reference Link
12:18 EDTINSYInsys Therapeutics puts active on sharp pullback
Insys Therapeutics June 50 and 55 puts are active on total put volume of 6,500 contracts (100 calls). June put option implied volatility is at 76, July is at 60 compared to its 90-day average of 62. Active put volume suggests traders taking positions for large upside price movement.
08:05 EDTINSYInsys Therapeutics pipeline growing, underappreciated, says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use